trending Market Intelligence /marketintelligence/en/news-insights/trending/qrychj7javo2_l86ojlcgg2 content esgSubNav
In This List

Evolent Health issues Q2 guidance

Blog

Fintech Intelligence Digital Newsletter: May 2021

Podcast

Street Talk Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs

Street Talk – Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs

Fintech Intelligence Digital Newsletter: April 2021


Evolent Health issues Q2 guidance

Evolent Health issued guidance for the second quarter and reaffirmed its outlook for full year 2018.

For the second quarter, the company expects adjusted revenue of about $139.0 million to $143.0 million, and adjusted EBITDA of approximately $3.0 million to $5.0 million.

For the first quarter, Evolent Health reported a net loss attributable to the company of $13.6 million, or 18 cents per share, compared to a net loss of $18.0 million, or 34 cents per share, in the year-ago period.

For full year 2018, the company continues to expect adjusted revenue of approximately $565.0 million to $585.0 million, and adjusted EBITDA of about $18.0 million to $23.0 million.